Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial

No abstract is available for this paper.

• Publication year

  2017

• Venue

  JAMA psychiatry

• Publication date

  2017-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamapsychiatry.2017.1838PMID 28700791PMCID PMC5710234
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Use of Tramadol for Management of Opioid Use Disorders: Rationale and Recommendations

  2018cited by this paper
• Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes

  2018cited by this paper
• Polysubstance use and misuse or abuse of prescription opioid analgesics: a multi-level analysis of international data

  2017cited by this paper
• Alpha₂-adrenergic agonists for the management of opioid withdrawal.

  2016cited by this paper
• Opioid agonist treatment for pharmaceutical opioid dependent people.

  2016cited by this paper
• Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio

  2015cited by this paper
• Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model.

  2015cited by this paper
• The Pharmacogenetics of Tramadol

  2015cited by this paper
• Barriers to Primary Care Physicians Prescribing Buprenorphine

  2014cited by this paper
• Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.

  2014cited by this paper
• Trial of Tramadol Plus Gabapentin for Opioid Detoxification

  2014cited by this paper
• Clinician beliefs and attitudes about buprenorphine/naloxone diversion.

  2013cited by this paper
• Perceived relapse risk and desire for medication assisted treatment among persons seeking inpatient opiate detoxification.

  2013cited by this paper
• Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial.

  2013cited by this paper
• Tramadol versus Methadone for Treatment of Opiate Withdrawal: A Double-Blind, Randomized, Clinical Trial

  2012cited by this paper
• Impact of CYP2D6 Genetic Polymorphism on Tramadol Pharmacokinetics and Pharmacodynamics

  2012cited by this paper
• Societal costs of prescription opioid abuse, dependence, and misuse in the United States.

  2011cited by this paper
• The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.

  2011cited by this paper
• A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis.

  2010cited by this paper
• Mortality among drug users after discharge from inpatient treatment: an 8-year prospective study.

  2010cited by this paper
• Tramadol acts as a weak reinforcer in the rat self-administration model, consistent with its low abuse liability in humans.

  2010cited by this paper
• Tramadol versus clonidine in management of heroin withdrawl.

  2010cited by this paper
• Brief buprenorphine detoxification for the treatment of prescription opioid dependence: a pilot study.

  2009cited by this paper
• Economic Burden of Prescription Opioid Misuse and Abuse

  2009cited by this paper
• Modest opioid withdrawal suppression efficacy of oral tramadol in humans

  2007cited by this paper
• Tramadol versus buprenorphine for the management of acute heroin withdrawal: a retrospective matched cohort controlled study.

  2006cited by this paper
• Tramadol versus Buprenorphine for the Treatment of Opiate Withdrawal

  2004cited by this paper
• The Use of Tramadol for Acute Heroin Withdrawal

  2004cited by this paper
• Predicting completion of outpatient opioid detoxification with clonidine.

  2003cited by this paper
• The Clinical Opiate Withdrawal Scale (COWS)

  2003cited by this paper
• Affinity, potency and efficacy of tramadol and its metabolites at the cloned human µ-opioid receptor

  2000cited by this paper
• Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl.

  1996cited by this paper
• Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic.

  1992cited by this paper
• Abuse potential and pharmacological comparison of tramadol and morphine.

  1991cited by this paper
• Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids.

  1988cited by this paper
• Two new rating scales for opiate withdrawal.

  1987cited by this paper
• Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts.

  1985cited by this paper
• Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

  1978cited by this paper

• Randomized, placebo-controlled trial of gabapentin during outpatient buprenorphine-assisted taper and transition to injectable naltrexone

  2025cites this paper
• Treating Opioid Use Disorder and Opioid Withdrawal in the Context of Fentanyl.

  2025cites this paper
• Examining the Severity and Progression of Illicitly Manufactured Fentanyl Withdrawal: A Quasi-experimental Comparison

  2024cites this paper
• Improving Opioid Use Disorder Treatment With Buprenorphine: A Quality Improvement Project

  2024cites this paper
• The Effectiveness of Tramadol in Pain Relief in Chronic Diseases: A Review Based on Clinical Trials

  2024cites this paper
• A novel tramadol–polycaprolactone implant could palliate heroin conditioned place preference and withdrawal in rats: behavioral and neurochemical study

  2024cites this paper
• A narrative review of outcome measures used in drug and alcohol inpatient withdrawal treatment research.

  2023cites this paper
• Iteration is not solving the opioid crisis, it’s time for transformation

  2023cites this paper
• IUPHAR review - Data-driven Computational Drug Repurposing Approaches for Opioid Use Disorder.

  2023cites this paper
• Tramadol poisoning and its management and complications: a scoping review

  2023cites this paper
• Efficacy and safety of tramadol in the treatment of opioid withdrawal: A meta-analysis of randomized controlled trials.

  2023cites this paper
• Operational definition of precipitated opioid withdrawal

  2023cites this paper
• Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings

  2023cites this paper
• Buprenorphine for High-dose Tramadol Dependence: A Case Report of Successful Outpatient Treatment

  2022cites this paper
• Fentanyl Withdrawal: Understanding Symptom Severity and Exploring the Role of BMI on Withdrawal Symptoms and Clearance.

  2022cites this paper
• Managing acute opioid withdrawal with tramadol during COVID-19 lockdown in a peri-urban setting

  2022cites this paper
• Delivering transcutaneous auricular neurostimulation (tAN) to improve symptoms associated with opioid withdrawal: results from a prospective clinical trial

  2022cites this paper
• Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper

  2022cites this paper
• Urinalysis based assessment of compliance and drug use patterns in patients prescribed tramadol: A cross-sectional study from a tertiary care centre.

  2022cites this paper
• Clinical Management of Opioid Withdrawal.

  2022cites this paper
• Opioid Tapering/Detoxification Protocols, A Compendium: Narrative Review.

  2021cites this paper
• Wireless electroencephalography (EEG) to monitor sleep among patients being withdrawn from opioids: Evidence of feasibility and utility.

  2021cites this paper
• Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients

  2021cites this paper
• Expert review and recommendations for the management of acute, chronic, and neuropathic pain in Qatar.

  2021cites this paper
• Pharmacological management of psychoactive substance withdrawal syndrome

  2021cites this paper
• Opioid Treatments for Chronic Pain

  2020cites this paper
• Effects of Separate and Combined Chronic Ingestion of Tramadol and Codeine on Aggressive Behaviour among Female Albino Rats

  2020cites this paper
• Interactions between reproductive transitions during aging and addiction: promoting translational crosstalk between different fields of research.

  2020influential citation
• The effects of cytochrome P450 2D6 inhibitors on a high-dose tramadol taper for medically supervised opioid withdrawal: a retrospective chart review

  2020cites this paper
• Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome.

  2020cites this paper
• Tramadol for the Management of Opioid Withdrawal: A Systematic Review of Randomized Clinical Trials

  2020cites this paper
• New directions in the treatment of opioid withdrawal.

  2020cites this paper
• Sirt3 mediated by lentiviral vector in the periaqueductal gray suppresses morphine withdrawal in rats: A preliminary study

  2019cites this paper
• Clinical Trials for Opioid Use Disorder.

  2019cites this paper
• Endogenous Opiates and Behavior: 2017.

  2019cites this paper
• Therapeutic experience with tramadol for opioid dependence in a patient with chronic low back pain: a case report

  2019cites this paper
• A Systematic Review of Laboratory Evidence for the Abuse Potential of Tramadol in Humans

  2019cites this paper
• The relationship between pupil diameter and other measures of opioid withdrawal during naloxone precipitated withdrawal.

  2019cites this paper
• Present and Future Pharmacological Treatments for Opioid Addiction

  2019cites this paper
• Error in Key Points and Conclusions.

  2018cites this paper
• Codeine rescheduling and the GP

  2018cites this paper
• Opioid Prescribing in Orthopaedic Surgery: An Evolving Paradigm

  2018cites this paper
• DARK Classics in Chemical Neuroscience: Opium, a Friend or Foe.

  2018cites this paper
• Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes

  2018cites this paper
• Use of Tramadol for Management of Opioid Use Disorders: Rationale and Recommendations

  2018cites this paper
• Retard-Tramadol für die medikamentengestützte Opiatentgiftung

  2017cites this paper
• Tramadol Extended Release and Opioid Withdrawal Management-Legal Implications.

  2017cites this paper
• Tramadol Extended-Release and Opioid Withdrawal Management-Legal Implications-Reply.

  2017cites this paper
• Errors in Abstract and Discussion.

  2017cites this paper
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (The CANVAS Program)1

  2017cites this paper
• EFFICACY AND SAFETY OF TAPENTADOL IN OPIOID WITHDRAWAL MANAGEMENT: A LONGITUDINAL QUASI-EXPERIMENTAL STUDY

  year unknowncites this paper